Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr30.40 SEK
Change Today -0.20 / -0.65%
Volume 18.0K
HMED On Other Exchanges
As of 11:29 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

hansa medical research ab (HMED) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/10/15 - kr70.76
52 Week Low
08/14/14 - kr15.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

hansa medical research ab (HMED) Related Businessweek News

No Related Businessweek News Found

hansa medical research ab (HMED) Details

Hansa Medical AB develops novel immunomodulatory enzymes for the treatment of rare and acute conditions characterized by pathogenic antibodies. The company’s lead drug candidate is IdeS, an antibody degrading enzyme, which is in Phase II study for use in transplantation and rare autoimmune diseases. It also develops HBP-assay, a diagnostic method for predicting severe sepsis at emergency wards; and is involved in the research project of EndoS, an antibody-modulating bacterial enzyme to modify the sugar structure of antibodies, as well as to treat the autoimmune diseases and other inflammatory conditions, such as autoimmune hemolysis, systemic lupus, and glomerulonephritis. Hansa Medical AB was formerly known as Hansa Medical Utvecklings AB and changed its name to Hansa Medical AB in 2007. Hansa Medical AB was founded in 2001 and is based in Lund, Sweden.

14 Employees
Last Reported Date: 04/16/15
Founded in 2001

hansa medical research ab (HMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hansa medical research ab (HMED) Key Developments

Hansa Medical AB Announces the Results from the Phase I Trial of Candidate Drug

Hansa Medical AB announced that the results from the phase I trial of its candidate drug. The trial was a first-in-man, double blind, randomized study with single-ascending doses of IdeS in twenty-nine healthy male subjects who were given intravenous doses of placebo or IdeS at 0.01, 0.04, 0.12 and 0.24 mg/kg body weight. IdeS was considered safe with no serious adverse events. Furthermore, IdeS converted plasma IgG into single cleaved IgG (scIgG) with impressive efficacy within minutes after administration. ScIgG has compromised effector functions with reduced binding to Fc receptors and reduced Fc mediated cytotoxicity (Brezski et al., 2009), i.e. the function of the antibodies is significantly reduced. Full or close to full effect on IgG, i.e. conversion into F(ab')2 and Fc fragments (complete IgG cleavage), was seen in all subjects dosed with 0.12 and 0.24 mg/kg BW. IgG reached the lowest concentrations 2-24 hours after dosing and remained low for more than a week, until newly synthesized IgG appeared in the plasma. Data demonstrated that the entire extracellular IgG pool and not only the plasma pool, is cleaved by IdeS. This remarkable efficacy of IdeS outcompetes the effect of plasma exchange, which typically leaves approximately 35% remaining IgG. Furthermore, 24 hours after a plasma exchange the IgG levels are restored to 60%.

Hansa Medical AB Announces First Patient in Ides Phase II Study Transplanted

Hansa Medical AB announced that the first patient after treatment with IdeS in a recently initiated Phase II study has been transplanted from a deceased donor. The phase II study that can include up to 10 patients is performed at Uppsala University Hospital and Karolinska University Hospital. The study will evaluate the safety, tolerability and efficacy of IdeS in kidney transplantation of sensitized patients. The patient was treated and transplanted in Uppsala. The study is also aimed at identifying the appropriate dose that in the majority of patients will result in anti-HLA antibody levels acceptable for transplantation within 24 hours from dosing. It is expected that top-line results will be available around half-year 2016.

Hansa Medical AB Presents at BIO International Convention 2015, Jun-16-2015 04:00 PM

Hansa Medical AB Presents at BIO International Convention 2015, Jun-16-2015 04:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Emanuel Björne, Corporate Development Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HMED:SS kr30.40 SEK -0.20

HMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HMED.
View Industry Companies

Industry Analysis


Industry Average

Valuation HMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 122.9x
Price/Book 21.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 150.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANSA MEDICAL RESEARCH AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at